SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.
A Phase Ia/Ib, First-in-Human, Open-Label, Multicenter, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Efficacy of SG2501 in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.
Sponsor: Hangzhou Sumgen Biotech Co., Ltd.
A PHASE1 clinical study on Hematological Malignancy and Lymphoma, this trial is terminated or withdrawn. The trial is conducted by Hangzhou Sumgen Biotech Co., Ltd. and has accumulated 8 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Change History
8 versions recorded-
Apr 2025 — Present [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Sep 2024 — Apr 2025 [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
Mar 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
May 2023 — Mar 2024 [monthly]
Recruiting PHASE1
▶ Show 3 earlier versions
-
Mar 2023 — May 2023 [monthly]
Recruiting PHASE1
-
Sep 2022 — Mar 2023 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Apr 2022 — Sep 2022 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Hangzhou Sumgen Biotech Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Atlanta, United States
- • Canton, United States
- • Charlotte, United States
- • Dallas, United States
- • Durham, United States
- • Hackensack, United States
- • Hawthorne, United States
- • Winston-Salem, United States